In this paper, we give an overview of a multiscale approach for advanced process modeling and discuss the latest progress.
This makes the ESRD group a valuable "model" for advanced and rapidly progressing atherosclerosis, useful for clinical studies.
Combinations of endocrine therapies with targeted agents in the first-line setting for advanced breast cancer progressing on NSAIs have shown mixed results.
In the phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib (EVOLVE-1 NCT01035229), Zhu and colleagues assessed the efficacy and safety of everolimus for advanced HCC after sorafenib failure [ 93].
Maintenance therapy for advanced NSCLC not progressing after a first cisplatin doublet became an option [ 3] but the cost-effectiveness of this strategy has not been well-established [ 16– 20].
This Phase II, multicenter, randomized, open label study (Study E7389-G000-209; NCT00879086) recruited patients with locally recurrent or MBC who had received prior taxane therapy, at least one prior cytotoxic chemotherapy for advanced disease, and progressed during or after their last anti-cancer therapy.
Assessments of other therapies for advanced cancer are in progress: a technology guidance appraisal of vinorelbine and capecitabine use for advanced breast cancer was recently published by NICE NICEE, 2002b; 2003).
The rarity and paucity of well designed clinical studies of medical and/or surgical therapy for advanced penile cancer have hampered progress in the treatment of this disease.
The DTI sequence was a Works-in-Progress package for advanced EPI diffusion imaging, developed by Thorsten Feiweier, Siemens AG, Healthcare Sector, Erlangen, Germany.
The treatment and outcomes for advanced prostate cancer have experienced significant progress over recent years.
Although there was no remarkable progress in chemotherapy for advanced gastric cancer in the 1990s, in the early 2000s new agents and optional treatments emerged.
